Novartis wins EU approval for Rhapsido in chronic spontaneous urticaria
PUBT · 20h ago
Share
Listen to the news
- European Commission cleared Novartis oral BTK inhibitor Rhapsido (remibrutinib) for chronic spontaneous urticaria in adults with inadequate response to H1-antihistamines.
- Decision makes Rhapsido first oral targeted treatment authorized for CSU in Europe.
- Novartis said Rhapsido will be taken twice daily with no lab monitoring required.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604270115OMX_____CNEWS_EN_GNW1001178018_en) on April 27, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved